Spire Wealth Management
DMRA

Spire Wealth Management’s Damora Therapeutics DMRA Stock Holding History

Spire Wealth Management’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-81
Closed -$949 – 2212
2024
Q2 		$949 Buy
81
+1
+1% +$16 ﹤0.01% 2130
2024
Q1 		$1.56K Hold
80
– – ﹤0.01% 2142
2023
Q4 		$1.32K Hold
80
– – ﹤0.01% 2219
2023
Q3 		$1.44K Buy
+80
New +$3.14K ﹤0.01% 2192

Other funds holding DMRA

Novo Holdings A/S
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 107.05% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Tower Research Capital (TRC)
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Harbour Investments
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return
Danske Bank
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Spire Wealth Management's DMRA Position: Q3 2024 in Review

Spire Wealth Management sold out of Damora Therapeutics (DMRA) in Q3 2024, closing a stake of 81 shares — an estimated $949 sold.

Spire Wealth Management first reported a position in DMRA in Q3 2023 and held it in 4 quarters. The position peaked at $1.56K in Q1 2024. 10 funds tracked by Wall St. Rank hold DMRA as of Q3 2024.

  • Spire Wealth Management reported no remaining Damora Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Spire Wealth Management sold 81 Damora Therapeutics shares in Q3 2024, an estimated $949.
  • Spire Wealth Management first reported a position in Damora Therapeutics in Q3 2023 and held it in 4 quarters.
  • Spire Wealth Management's Damora Therapeutics position peaked at $1.56K in Q1 2024.
  • 10 funds tracked by Wall St. Rank held Damora Therapeutics as of Q3 2024.

Based on Spire Wealth Management's 13F filing for Q3 2024, filed 15 Oct 2024.